Efficacy of anti-CTLA-4 after progression on anti-PD1 therapy in advanced melanoma

被引：0
|
作者：
Aya Moreno, F. [1 ]
Fernandez-Martinez, A. [1 ]
Gaba, L. [1 ]
Victoria, I. [1 ]
Arance Fernandez, A. M. [1 ]
机构：
[1] Hosp Clin Barcelona, Med Oncol, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15P
引用
收藏
页码：6 / 6
页数：1
相关论文
共 50 条
  • [31] Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center
    Afzal, Muhammad Z.
    Shirai, Keisuke
    [J]. MELANOMA RESEARCH, 2018, 28 (04) : 341 - 347
  • [32] Impact of body composition on outcomes from anti-PD1+/- anti-CTLA-4 treatment in melanoma
    Young, Arissa C.
    Quach, Henry T.
    Song, Haocan
    Davis, Elizabeth J.
    Moslehi, Javid J.
    Ye, Fei
    Williams, Grant R.
    Johnson, Douglas B.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [33] Analysis of CTLA-4 gene polymorphisms in patients with advanced melanoma treated with anti-CTLA-4 therapy.
    Queirolo, P.
    Morabito, A.
    Piccioli, P.
    Lastraioli, S.
    Callegari, S.
    Camoriano, M.
    Ascierto, P. A.
    Laurent, S.
    Dozin, B.
    Pistillo, M. P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer
    Patel, Sandip P.
    Guadarrama, Elizabeth
    Chae, Young Kwang
    Dennis, Michael J.
    Powers, Benjamin C.
    Liao, Chih-Yi
    Ferri, William A.
    George, Thomas J.
    Sharon, Elad
    Ryan, Christopher W.
    Othus, Megan
    Lopez, Gabby
    Blanke, Charles D.
    Kurzrock, Razelle
    [J]. CANCER, 2024, 130 (17) : 2918 - 2927
  • [35] Evaluating the safety of anti-CTLA-4 therapy in the elderly with unresectable melanoma
    Chandra, Sunandana
    Madden, Kathleen M.
    Kannan, Rajni
    Pavlick, Anna C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy
    Rogiers, Aljosja
    Dimitriou, Florentia
    Lobon, Irene
    Harvey, Catriona
    Vergara, Ismael A.
    da Silva, Ines Pires
    Lo, Serigne N.
    Scolyer, Richard A.
    Carlino, Matteo S.
    Menzies, Alexander M.
    Long, Georgina V.
    [J]. EUROPEAN JOURNAL OF CANCER, 2024, 198
  • [37] Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
    Subrahmanyam, Priyanka B.
    Dong, Zhiwan
    Gusenleitner, Daniel
    Giobbie-Hurder, Anita
    Severgnini, Mariano
    Zhou, Jun
    Manos, Michael
    Eastman, Lauren M.
    Maecker, Holden T.
    Hodi, F. Stephen
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [38] Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action
    Willsmore, Zena N.
    Coumbe, Ben G. T.
    Crescioli, Silvia
    Reci, Sara
    Gupta, Ayushi
    Harris, Robert J.
    Chenoweth, Alicia
    Chauhan, Jitesh
    Bax, Heather J.
    McCraw, Alexa
    Cheung, Anthony
    Osborn, Gabriel
    Hoffmann, Ricarda M.
    Nakamura, Mano
    Laddach, Roman
    Geh, Jenny L. C.
    MacKenzie-Ross, Alastair
    Healy, Ciaran
    Tsoka, Sophia
    Spicer, James F.
    Josephs, Debra H.
    Papa, Sophie
    Lacy, Katie E.
    Karagiannis, Sophia N.
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2021, 51 (03) : 544 - 556
  • [39] Combination Therapy with Anti-CTLA-4 and Anti-PD-1 Leads to Distinct Immunologic Changes In Vivo
    Das, Rituparna
    Verma, Rakesh
    Sznol, Mario
    Boddupalli, Chandra Sekhar
    Gettinger, Scott N.
    Kluger, Harriet
    Callahan, Margaret
    Wolchok, Jedd D.
    Halaban, Ruth
    Dhodapkar, Madhav V.
    Dhodapkar, Kavita M.
    [J]. JOURNAL OF IMMUNOLOGY, 2015, 194 (03): : 950 - 959
  • [40] Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
    Lipson, Evan J.
    Drake, Charles G.
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (22) : 6958 - 6962
12345